BioCryst Pharma (BCRX) Tops Q1 EPS by 2c

BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $68.4 million versus the consensus estimate of $71.47 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c
• Yum! Brands (YUM) PT Lowered to $180 at Argus